Achmea Investment Management B.V. lowered its holdings in Amgen, Inc. (NASDAQ:AMGN) by 21.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 81,446 shares of the medical research company’s stock after selling 21,960 shares during the period. Amgen comprises 0.8% of Achmea Investment Management B.V.’s holdings, making the stock its 22nd largest position. Achmea Investment Management B.V.’s holdings in Amgen were worth $14,023,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of the business. Financial Advisory Service Inc. boosted its position in Amgen by 0.3% in the second quarter. Financial Advisory Service Inc. now owns 1,974 shares of the medical research company’s stock worth $340,000 after purchasing an additional 5 shares during the last quarter. Jackson Grant Investment Advisers Inc. boosted its position in Amgen by 0.8% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after purchasing an additional 5 shares during the last quarter. Capital Advisors Ltd. LLC boosted its position in Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,103 shares of the medical research company’s stock worth $190,000 after purchasing an additional 7 shares during the last quarter. Ballentine Partners LLC lifted its position in shares of Amgen by 0.3% during the 2nd quarter. Ballentine Partners LLC now owns 3,441 shares of the medical research company’s stock valued at $620,000 after buying an additional 9 shares during the last quarter. Finally, Hudock Capital Group LLC lifted its position in shares of Amgen by 0.5% during the 2nd quarter. Hudock Capital Group LLC now owns 1,921 shares of the medical research company’s stock valued at $330,000 after buying an additional 10 shares during the last quarter. 78.62% of the stock is currently owned by institutional investors and hedge funds.
AMGN has been the topic of a number of recent research reports. Mizuho reaffirmed a “buy” rating and set a $183.00 price target (down previously from $195.00) on shares of Amgen in a research report on Monday, August 21st. Cann reaffirmed a “buy” rating on shares of Amgen in a research report on Monday, August 28th. Oppenheimer reaffirmed a “buy” rating and set a $203.00 price target on shares of Amgen in a research report on Thursday, September 7th. Royal Bank of Canada initiated coverage on Amgen in a research report on Thursday, September 14th. They set a “sector perform” rating and a $192.00 price target on the stock. Finally, BMO Capital Markets reaffirmed a “hold” rating and set a $199.00 price target on shares of Amgen in a research report on Monday, September 25th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $190.22.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. The business had revenue of $5.77 billion for the quarter, compared to analysts’ expectations of $5.75 billion. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The firm’s quarterly revenue was down .7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.02 EPS. analysts expect that Amgen, Inc. will post 12.66 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 8th. Investors of record on Thursday, February 15th will be issued a dividend of $1.32 per share. This is a boost from Amgen’s previous quarterly dividend of $1.15. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $5.28 dividend on an annualized basis and a yield of 2.98%. Amgen’s dividend payout ratio is 41.55%.
Amgen announced that its Board of Directors has initiated a share repurchase program on Wednesday, October 25th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to buy shares of its stock through open market purchases. Shares buyback programs are often a sign that the company’s board believes its stock is undervalued.
In related news, Director Carbonnel Francois De sold 4,000 shares of the stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total transaction of $694,440.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $185.95, for a total value of $283,573.75. The disclosure for this sale can be found here. Insiders have sold a total of 8,575 shares of company stock worth $1,509,339 in the last three months. 0.19% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: “Amgen, Inc. (AMGN) Shares Sold by Achmea Investment Management B.V.” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://sportsperspectives.com/2017/12/16/amgen-inc-amgn-shares-sold-by-achmea-investment-management-b-v.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.